The ASCO safety data is incrementally positive but not transformative — the stock's primary catalyst remains the MIRACLE trial unblinding in June 2026. Monitor for the unblinding results, which will determine the drug's approvability path. The company's $15M market cap and need for additional financing create binary risk around the trial outcome.
Price Chart
Executive Summary
Moleculin Biotech presented a pooled analysis at ASCO 2026 showing no detectable cardiotoxicity for its lead drug Annamycin across 90 patients, with independent review by Cleveland Clinic. The data reinforces the drug's differentiated safety profile as the pivotal Phase 2b/3 MIRACLE trial advances, with unblinding of the first 45 patients on track for June 2026.
Key Facts
- Pooled analysis of 90 patients across five completed trials showed no statistically significant change in LVEF (mean difference -0.12%; p=0.84)
- Median cumulative Annamycin dose was 660 mg/m², with exposures up to 2,970 mg/m² — far exceeding conventional anthracycline lifetime limits
- Independent cardiac review conducted by Cleveland Clinic Division of Cardiovascular Medicine
- Phase 1b/2 AML study demonstrated 50% CR rate, 60% CRc rate, and median OS of 12.39 months
- Unblinding from first 45 patients of the pivotal Phase 2b/3 MIRACLE trial is on track for June 2026
- Company is a Phase 3 clinical-stage biotech with a $15M market cap and will require significant additional financing
Financial Impact
No financial data in filing; clinical-stage company with no reported revenue. Key catalyst is the upcoming MIRACLE trial unblinding in June 2026.
Risk Factors
- Company requires significant additional financing with no commitments in place
- MIRACLE trial unblinding in June 2026 is the key binary catalyst — safety data alone does not de-risk efficacy
- Small dataset (90 patients) with no randomized controlled data yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018819 |
| Exhibit: ex_969652.htm | 0001437749-26-018819 |
| Document: 0001437749-26-018819-index-headers.html | 0001437749-26-018819 |
| Document: 0001437749-26-018819-index.html | 0001437749-26-018819 |
| Document: 0001437749-26-018819.txt | 0001437749-26-018819 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $6.19 | awaiting T+20 | — | $9.27 (+49.68%) |
Oct 16, 2026 11d ago | 8-K | $0.2804 | awaiting T+20 | — | $9.27 (+3204.21%) |
Oct 9, 2026 17d ago | 8-K | $0.4139 | awaiting T+20 | — | $9.27 (+2138.46%) |
Oct 5, 2026 22d ago | 8-K | $0.4766 | awaiting T+20 | — | $9.27 (+1843.98%) |
Sep 29, 2026 28d ago | 8-K | $0.5264 | awaiting T+20 | — | $9.27 (+1660.07%) |
Sep 29, 2026 28d ago | Press Release | $0.5264 | awaiting T+20 | — | $9.27 (+1660.07%) |
Sep 28, 2026 29d ago | 8-K | $0.5690 $7.09 | ▲ +1145.17% | ▲ +1145.20% | $9.27 (+1528.30%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $9.27 (+1440.06%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $9.27 (+1655.07%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $9.27 (−1681.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers